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CARDIOVASCULAR DISEASE—Hypercholesterolemia
PCV24
WHAT IS THE RELEVANCE OF AGE GROUPS IN SECONDARY
PREVENTION OF CARDIOVASCULAR EVENTS? A COST—
UTILITY ANALYSIS IN MEXICO
Mould Quevedo JF, Contreras I, Salinas—Escudero G, Garduño J
Social Security Mexican Institute, México D.F, México
OBJECTIVES: This research estimates incremental cost-utility
ratios for atorvastatin, simvastatin and pravastatin for treatment
of patients with hypercholesterolemia in secondary prevention
and various age groups. METHODS: By using a Markov model
with ﬁve ﬁnal outcomes, namely angina pectoris (AP), myocar-
dial infarction (MI), cerebrovascular disease (CVD), absence of
cardiovascular events and death, the medical care cost–utility in
the treatment of patients with hypercholesterolemia was esti-
mated. The following age groups were identiﬁed: 41–50 years,
51–60 years, 61–70 years and 71–80 years. The follow-up period
was ten years. A 5% discount rate was used for cost-utility
analysis. The perspective was that of the National Health
System. Quality-adjusted life-year estimates (QALYs) for each
ﬁnal outcome were obtained through a survey among cardiolo-
gists with clinical experience and life extension tables in the lit-
erature. Life years adjusted by life quality were constructed.
Costs per age group and type of event were obtained by review-
ing clinical records. Probabilistic sensitivity analysis was per-
formed and acceptability curves were constructed. RESULTS:
Costs and utilities vary among the various age groups. The
lowest annual average medical care cost per patient corresponds
to patients in the 41–50 year age group (US $33,000), and 
the highest among patients in the 71–80 year age group (US
$101,632). The 41–50 year age group produced 5.8 QALYs
being the highest, and the 71–80 year age group produced the
lowest—an average of 0.5 QALYs. In all age groups, atorvas-
tatin turned out to be the dominant treatment. CONCLUSIONS:
The use of atorvastatin in Mexico is the more cost-utility treat-
ment in patients with hypercholesterolemia in secondary pre-
vention in various age groups, but incremental cost–utility ratios
among older patients are actually the highest.
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COST EFFECTIVENESS OF ATORVASTATIN (LIPITOR) AS
SINGLE THERAPY AND DUAL THERAPY WITH EZETIMIBE
(ZETIA)
Bui T, Harrison DL
University of Oklahoma Health Sciences Center, Oklahoma City, OK,
USA
OBJECTIVES: To determine the average and incremental cost-
effectiveness of two treatment options, single therapy with 
atorvastatin and dual therapy with atorvastatin plus ezetimibe.
METHODS: Decision analyses were used to construct the deci-
sion trees for the two therapies and three LDL cholesterol goals.
Data came from NHANES III and included patient demographic
variables and patient laboratory values. Analyses were done
from the provider’s perspective for a period of one year.
RESULTS: For the LDL cholesterol goal < 160mg/dl, the average
cost-effectiveness ratios were $959 for single therapy and $1,747
for combination therapy, with an incremental cost-effectiveness
ratio of $88,171. For the LDL cholesterol goal < 130mg/dl, the
average cost-effectiveness ratios were $1383 for single therapy
and $2324 for dual therapy, with an incremental cost effective-
ness ratio of $23,564. In the group with LDL cholesterol goal <
100mg/dl, the average cost-effectiveness ratios were $1195 for
single therapy and $1735 for dual therapy, with an incremental
cost-effectiveness ratio of $5581. All results were robust to wide
variations in costs and probabilities of effectiveness. CONCLU-
SION: There were no signiﬁcant increased beneﬁts to using 
dual therapy among patients with established LDL cholesterol
treatment goals of 160mg/dl and 130mg/dl; therefore, single
therapy with atorvastatin appears to be the dominant strategy.
When the established LDL cholesterol goal is lowered to 
100mg/dl, dual therapy appears to be more cost-effective, and
the increased costs required to achieve an additional successful
outcome with dual therapy may be potentially considered
acceptable for providers.
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COST-EFFECTIVENESS OF EZETIMIBE CO-ADMINISTRATION
IN CHD PATIENTS NOT AT GOAL WITH CURRENT STATIN
THERAPY IN HONG KONG
Lee VW1, Chan WK2,Alemao E3,Yin D3, Cook JR4, Lee BS5,
Chong AC2,Tomlinson B1,Wong JC5, Lee KKC1
1The Chinese University of Hong Kong, Shatin, Hong Kong, China;
2United Christian Hospital, Kwun Tong, Hong Kong, China; 3Merck &
Co., Inc, Whitehouse Station, NJ, USA; 4Merck & Co., Inc, Blue Bell,
PA, USA; 5Prince of Wales Hospital, Shatin, Hong Kong, China
While treatment guidelines recommend lowering cholesterol to
target levels appropriate for CHD patients, many remain above
goal on current lipid lowering therapy and hence unable to get
the maximum beneﬁt of cholesterol reduction. For these patients,
a recently published clinical trial showed that ezetimibe co-
administration with existing statin therapy gets 72% of patients
to NCEP II goal versus 19% among patients continuing on exist-
ing therapy. OBJECTIVE: To assess cost effectiveness of 
Ezetimibe 10mg (EZ10) co-administration in CHD patients not
attaining goal (LDL-C > 2.59mmol/dL) while on statin therapy
(atorvastatin, and simvastatin). METHOD: Decision-analytic
model was developed to project lifetime costs and beneﬁts of
lipid therapy. Clinical trial data were used to estimate LDL-C
reductions for different treatment strategies. Effect of lipid reduc-
tions on CHD event rates was estimated using Framingham risk
equations and Hong Kong national statistics on nonCHD-related
mortality. Direct costs of CHD events and prices for lipid low-
ering therapy in Hong Kong were used to project lifetime costs.
The model was run for a population consisting of all patients on
simvastatin and atorvastatin in an observational lipid lowering
treatment study in Hong Kong involving patients initiated on a
statin and had not reached goal at the ﬁrst lipid measurement
after treatment. RESULTS: Mean age of study cohort of 67 CHD
patients was 64.7 (SD10.8) years and 30% were female with
mean LDL-C of 3.23mmol/L and TC of 4.85mmol/L. EZ10 co-
administered with statin compared to statin titration is projected
to increase life expectancy in this patient cohort by 0.45 years
with C/LY of $7387 and C/QALY of $7362. CONCLUSION:
Based on the model, treatment with ezetimibe co-administered
with statin for CHD patients not at goal is a cost-effective alter-
native to statin titration and is well below the $45,000
cost/QALY threshold commonly used in these analyses.
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AN ECONOMIC ANALYSIS OF EZETIMIBE/SIMVASTATIN
COMPARED TO USUAL CARE WITH STATIN MONOTHERAPY
Nag SS1, Sajjan SG1, Kamal Bahl S1, Cook JR2, Soffer J3, Rajagopal G2,
John A4, Heithoff K4, Markson LE1,Alexander CM1
1Merck & Co., Inc, West Point, PA, USA; 2Merck & Co., Inc, Blue Bell,
PA, USA; 3Merck & Co., Inc, Upper Gwynedd, PA, USA; 4Schering-
Plough Pharmaceuticals, Kenilworth, NJ, USA
OBJECTIVE: This economic analysis examined the implications
of using ezetimibe/simvastatin (E/S) as ﬁrst-line cholesterol
therapy compared to usual care with statin monotherapy.
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METHODS: The analysis consisted of: 1) a comparison of the
annual drug costs and percent LDL cholesterol (LDL-C) reduc-
tion for E/S and all statins/all doses; and 2) a model of a hypo-
thetical population of 1000 untreated coronary heart disease
(CHD) patients prescribed either E/S 10/20 or usual care with
statin monotherapy for ﬁve years. The model examined the cost
offsets or savings for E/S 10/20 compared to usual care, esti-
mated on a per patient basis due to projected differences in car-
diovascular disease (CVD) related hospitalization costs plus drug
costs (wholesale acquisition costs or WAC). Sensitivity analyses
included comparing E/S 10/20 with atorvastatin, and varying
drug acquisition costs. Key parameters of the model were as
follows: Usual care was assumed to provide LDL-C reduction
based upon the market-share weighted average of the reported
efﬁcacy for each statin. A log-linear regression based on end-
point trials estimated the relationship between LDL-C and CVD
event rates. The cost per patient with an event was estimated to
be $22,430 based upon analysis of CVD hospitalizations in
managed care claims. RESULTS: First, based upon WAC, the
annual drug cost per person for E/S was calculated as $842. For
high-efﬁcacy statins/doses (>40% LDL-C reduction), the annual
drug costs per person were $1080 (atorvastatin), $1379 (sim-
vastatin), and $803 (rosuvastatin). Second, compared to usual
care for ﬁve years of treatment, E/S 10/20 was estimated to result
in cost savings of $1568 per patient. Sensitivity analyses con-
ducted also showed cost savings for E/S. CONCLUSION: Com-
pared to usual care with statin monotherapy, treatment with E/S
10/20 was estimated to reduce CVD events and hospitalizations
among untreated CHD patients. This is projected to result in cost
savings over ﬁve years.
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COST-UTILITY ANALYSIS FOR STATINS IN MEXICO
Mould Quevedo JF, Contreras I, Nevarez A, García—Contreras F,
Constantino—Casas P, Garduño J
Social Security Mexican Institute, México D.F, México D.F, Mexico
OBJECTIVES: The purpose of this research is to estimate ator-
vastatin, simvastatin and pravastatin incremental cost-utility
ratios in Mexican patients with hypercholesterolemia in sec-
ondary prevention and ages between 45–70 years. METHODS:
A Markov model was used with ﬁve ﬁnal outcomes: angina pec-
toris (AP), myocardial infarction (MI), cerebrovascular disease
(CVD), absence of cardiovascular events and death. The follow
up period was ﬁve years, applying a 5% cost-utility discount
rate. The perspective was that of the National Health System
(only direct medical costs). The utility measure was obtained by
applying a survey to Mexican cardiologists with clinical experi-
ence and with the aid of survival tables published in the litera-
ture. The quality-adjusted life-years (QALYs) were constructed
for each ﬁnal outcome. Cost per event was obtained by review-
ing patient clinical records and expert opinion. The sensitivity
analysis was univariate and probabilistic and acceptability curves
were constructed. RESULTS: Annual average medical care costs
per event were: US$9906 for AP, US$8510 for MI, US$4720 for
CVD, US$2093 in the absence of cardiovascular events, and
US$13,744 in the case of death. The quality-adjusted life years
for MI were 1.2 years, for AP 2.9 years, for CVD 1.0 years, in
the absence of cardiovascular events 4.4 years, and in case of
death 0.0 years. For atorvastatin, the expected cost for treatment
during the follow up period was US$10,713, for simvastatin
US$15,873 and for pravastatin US$14,193. Finally, QALYs 
for atorvastatin, simvastatin and pravastatin during that same
period were 3.8; 3.5 and 3.7 years, respectively. CONCLU-
SIONS: Atorvastatin turned out to be dominant in Mexico and
offered the treatment with more cost-utility for patients with
hypercholesterolemia in secondary prevention, followed by
pravastatin and simvastatin. Stochastic sensitivity analysis
showed the same results.
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PREDICTORS OF COMPLIANCE AND PERSISTENCE TO
STATIN THERAPY AMONG TEXAS MEDICAID PATIENTS
Dastani H1, Shepherd M1, Sasane R2
1University of Texas at Austin, Austin,TX, USA; 2AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA
OBJECTIVES: This study assessed the predictors of compliance
and persistence to statin therapy among Texas Medicaid patients.
METHODS: A retrospective cohort-analysis using pharmacy
and medical claims of new statin users between September 1,
1999–August 31, 2001 was done. Compliance was assessed
using medication possession ratio (MPR), which is a ratio of the
sum of the days’ supply (except on the last prescription reﬁll
date) to the total number of days between the ﬁrst and last 
prescription reﬁll date. Persistence was deﬁned as the time to
therapy discontinuation or the failure to reﬁll a prescription
within 60 days of exhausting the last supply. The predictors of
compliance and persistence that were assessed included gender,
age, ethnicity, presence of disease conditions, and total number
of prescriptions other than statins. Logistic regression and Cox
regression models were used to assess the predictors. RESULTS:
Of the total (N = 7440) patients, 65.2% were females and the
mean age was 49.7 years (S.D. = 9.4 years). White, non-Hispanic
(42.7%), Hispanic (32.7%), and Black, non-Hispanic (22.5%)
formed the majority of the ethnic categories. The mean MPR was
0.7 (S.D. = 0.2) and 56.7% of the patients had an MPR of less
than 0.8. At the end of 310 days, only 50% of the patients were
still persistent with their therapy. The cumulative probability of
being persistent to therapy at the end of the 2-year period was
0.41. The predictors of improved compliance and persistence to
statin therapy were male gender, being non-Hispanic white, and
absence of disease conditions such as CHD, diabetes, and hyper-
tension. CONCLUSIONS: Adherence to statin therapy is sub-
optimal. There exists a gender gap as well as ethnic disparity
with regards to adherence. Steps need to be taken to promote
adherence in order to reduce the risk and the long-term costs
associated with CHD.
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COMPLIANCE WITH STATIN TREATMENT: THE EFFECT OF
SWITCHING TO ANOTHER STATIN AFTER TREATMENT
INITIATION
Thiebaud P1, Nichol MB1, Patel BV2
1University of Southern California, Los Angeles, CA, USA; 2MedImpact
Healthcare Systems, Inc, San Diego, CA, USA
OBJECTIVES: To determine how switching to a new statin after
treatment initiation affects new statin users’ compliance and per-
sistence, and to evaluate switching rates among ﬁve statins: ator-
vastatin, ﬂuvastatin, lovastatin, pravastatin, and simvastatin.
METHODS: The sample includes 24,035 patients over the 
age of 18 who were continuously eligible for two-years. These
patients are all new statin users as deﬁned by a one-year wash-
out period before the ﬁrst statin prescription. Patients with only
one claim or with claims covering more than 30 days of supply
were excluded. Their compliance is measured with the medica-
tion possession ration (MPR) and their persistence with the 
duration of continuous therapy. Logistic regression (simple or
weighed with propensity score for drug treatment assignment)
was used for compliance and censored regression for persistence.
RESULTS: Switching negatively impacts persistence (-14.5%
duration of continuous therapy) vs. no switch (p < 0.0001). The
